JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Quidel Corp

Slēgts

23.63 -1.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

23.46

Max

24.42

Galvenie mērījumi

By Trading Economics

Darbinieki

6,600

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+82.68% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-76M

1.7B

Iepriekšējā atvēršanas cena

25.58

Iepriekšējā slēgšanas cena

23.63

Quidel Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 21:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025. g. 4. aug. 21:21 UTC

Peļņas
Galvenie tirgus virzītāji

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025. g. 4. aug. 20:45 UTC

Peļņas

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025. g. 4. aug. 19:15 UTC

Galvenie tirgus virzītāji

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Nikkei May Rise on Fed Stimulus Hopes

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025. g. 4. aug. 21:30 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 21:21 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025. g. 4. aug. 21:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 20:25 UTC

Tirgus saruna

India Hits Back Over Russian Oil Purchases -- Market Talk

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss $938M >RIG

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss/Shr $1.06 >RIG

2025. g. 4. aug. 20:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025. g. 4. aug. 20:15 UTC

Peļņas

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025. g. 4. aug. 20:13 UTC

Peļņas

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025. g. 4. aug. 20:09 UTC

Peļņas

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025. g. 4. aug. 20:06 UTC

Peļņas

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025. g. 4. aug. 19:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 4. aug. 19:28 UTC

Tirgus saruna

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025. g. 4. aug. 19:07 UTC

Tirgus saruna

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025. g. 4. aug. 18:27 UTC

Tirgus saruna

Gold Climbs on Rate Cut Speculation -- Market Talk

Salīdzinājums

Cenas izmaiņa

Quidel Corp Prognoze

Cenas mērķis

By TipRanks

82.68% augšup

Prognoze 12 mēnešiem

Vidējais 41.67 USD  82.68%

Augstākais 60 USD

Zemākais 27 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Quidel Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

4

Pirkt

3

Turēt

1

Pārdot

Finanšu rādītāji

$

Par Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.